Tenured Life Sciences Executive Joins AI-Driven Drug
Discovery Company to Provide Strategic Guidance and Support
Pipeline Growth
LA
JOLLA, Calif., April 24,
2024 /PRNewswire/ -- Model Medicines, a leading human
health company specializing in generative AI-driven drug discovery,
today announced the appointment of Dr. Launa Aspeslet as
Senior Scientific & Clinical Advisor. In this role, Dr.
Aspeslet will provide strategic guidance and support to the
company's executive team as they continue to scale their AI-driven
drug discovery platform and advance their pipeline of novel
therapeutics.
Dr. Aspeslet brings over 25 years of progressive leadership and
management experience in the life sciences industry. She has a
proven track record in driving early-stage organizations to scale
and long-term maturity, working within multi-stakeholder
environments, guiding new product development, and enabling the
next generation of leaders through various stages of organizational
transformation.
"We are thrilled to welcome Dr. Aspeslet to the Model Medicines
team," said Dr. Daniel Haders, CEO
and Founder of Model Medicines. "Her deep expertise in the life
sciences industry, coupled with her experience in leading and
scaling organizations, will be invaluable as we continue to grow
and advance our mission to revolutionize drug discovery and
development."
Prior to joining Model Medicines, Dr. Aspeslet served as the
interim CEO of Edmonton Unlimited, where she was responsible for
empowering the organization to move into the next level of scale
and integration into the local and global innovation ecosystem. She
was also the Chief Operating Officer at Hepion Pharmaceuticals, a
NASDAQ-traded biotechnology company, and CEO of TRIO, a global
clinical research organization specializing in managing oncology
trials worldwide. Additionally, Dr. Aspeslet has provided strategic
guidance as a consultant for early-stage drug and medical device
companies and served as COO at Isotechnika Pharma Inc.
"I am thrilled to join Model Medicines at such a pivotal time in
the company's growth," said Dr. Aspeslet. "Throughout my career, I
have witnessed the immense challenges and opportunities in bringing
novel therapeutics to patients in need. Model Medicines is in
a rare space of companies that have achieved the 'The AI Pharma
Code': identified novel biology and new chemical entities,
zero-shot hit rates above 30% at concentrations below 20μM,
Tanimoto scores below 0.5, a diverse pipeline across biology and
disease, and a validated AI-generated compound in preclinical
animal models.
Dr. Aspeslet holds a Bachelor of Science degree in chemistry
from the University of Lethbridge and a
Doctor of Philosophy degree in Pharmaceutical Sciences from the
University of Alberta. She has a
Regulatory Affairs Certification (RAC) and is a graduate of the
Ivey Business School Executive Program at Western University. She also serves as Board Chair
at Applied Pharmaceutical Innovation, an Edmonton-based industry-led not-for-profit
organization that supports the development of life science products
and companies in Canada.
PAPERS:
"Discovery of RdRp Thumb-1 as a novel broad-spectrum antiviral
family of targets and MDL-001 as a potent broad-spectrum inhibitor
thereof - Part I: A Bioinformatics and Deep Learning Approach"
"ChemPrint: An AI-Driven Framework for Enhanced Drug
Discovery"
ABOUT MODEL MEDICINES:
Model Medicines is a generative
AI-driven human health company that uses AI to model all of
chemistry and human biology to accelerate the creation of
life-changing drugs. The company was founded in 2019 to deliver on
the promise of AI drug discovery. With more than 192 compounds for
26 targets, they are delivering on the promise of AI drug
discovery. The company has developed a robust pipeline of
patent-pending therapeutics for oncology, infectious diseases,
gastric disorders, neurological disorders, and weight disorders.
The company is based in La Jolla,
CA. To learn more, visit www.modelmedicines.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/model-medicines-appoints-dr-launa-aspeslet-as-senior-scientific--clinical-advisor-302125486.html
SOURCE Model Medicines